Costs Associated With Changes in Antidepressant Treatment in a Managed Care Population With Major Depressive Disorder

被引:23
作者
Schultz, Jennifer [1 ]
Joish, Vijay [2 ]
机构
[1] Univ Minnesota, Dept Econ, Duluth, MN 55812 USA
[2] Sanofi Aventis, Dept Hlth Outcomes, Bridgewater, NJ USA
关键词
TREATMENT-RESISTANT DEPRESSION; STAR-ASTERISK-D; MEDICATION; THERAPY; RETRANSFORMATION; AUGMENTATION; VENLAFAXINE; SERTRALINE; ADHERENCE; FAILURE;
D O I
10.1176/ps.2009.60.12.1604
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: This study determined whether persons with major depressive disorder who switch or augment antidepressant therapy have higher health care costs and productivity losses than those who do not. Methods: Data from July 1, 2002, through June 30, 2006, were taken from a national employment-based medical and pharmacy claims database. Participants were required to have filled an antidepressant prescription, be treatment nave six months before the index prescription, be continuously enrolled in the benefits plan at least six months before and 12 months after the index prescription, and have at least one outpatient-based medical claim for major depressive disorder. Participants were categorized according to whether they switched, augmented, or maintained (that is, neither switched nor augmented) their antidepressant therapy in the 12 months after the index prescription. Productivity losses were defined as days absent from work for medical visits multiplied by average daily wage. Multivariate analyses (generalized linear models) were used to compare costs per person in the year after the index prescription, and univariate analyses (Wilcoxon tests) were used to compare productivity losses per person. Results: Of the 7,273 individuals who met study criteria, 40.3% switched, 1.5% augmented, and 58.2% maintained the index antidepressant therapy. After the analyses controlled for baseline characteristics, mean total and depression-related health care costs, respectively, in the year after the index prescription were significantly greater for switchers ($ 9,288 and $ 1,388 per person) and for augmenters ($ 9,350 and $ 1,027) than for maintainers ($ 6,151 and $ 723). Mean total and depression-related productivity losses, respectively, were significantly greater for switchers ($ 2,081 and $ 680) and augmenters ($ 2,010 and $ 587) than for maintainers ($ 1,424 and $ 437). Conclusions: Persons with major depressive disorder who switched or augmented antidepressant therapy within 12 months of treatment initiation had higher resource costs and productivity losses than those who did not. (Psychiatric Services 60: 1605-1611, 2009)
引用
收藏
页码:1604 / 1611
页数:8
相关论文
共 21 条
[1]  
[Anonymous], MATH STAT, DOI DOI 10.2307/1391852
[2]   The economics of women and depression: an employer's perspective [J].
Birnbaum, HG ;
Leong, SA ;
Greenberg, PE .
JOURNAL OF AFFECTIVE DISORDERS, 2003, 74 (01) :15-22
[3]  
Burton WN, 2007, AM J MANAG CARE, V13, P105
[4]   Methods for evaluating patient adherence to antidepressant therapy - A real-world comparison of adherence and economic outcomes [J].
Cantrell, CR ;
Eaddy, MT ;
Shah, MB ;
Regan, TS ;
Sokol, MC .
MEDICAL CARE, 2006, 44 (04) :300-303
[5]   Economic implications of treatment-resistant depression among employees [J].
Greenberg, P ;
Corey-Lisle, PK ;
Birnbaum, H ;
Marynchenko, M ;
Claxton, A .
PHARMACOECONOMICS, 2004, 22 (06) :363-373
[6]   The economic burden of depression in the United States: How did it change between 1990 and 2000? [J].
Greenberg, PE ;
Kessler, RC ;
Birnbaum, HG ;
Leong, SA ;
Lowe, SW ;
Berglund, PA ;
Corey-Lisle, PK .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (12) :1465-1475
[7]   Quality of treatment and disability compensation in depression:: Comparison of 2 nationally representative samples with a 10-year interval in Finland [J].
Honkonen, Teija I. ;
Aro, Timo A. ;
Isometsa, Erkki T. ;
Virtanen, E. Marianna ;
Katila, Heikki O. .
JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (12) :1886-1893
[8]   Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder [J].
Khandker, Rezaul K. ;
Kruzikas, Denise T. ;
McLaughlin, Trent P. .
JOURNAL OF MANAGED CARE PHARMACY, 2008, 14 (05) :426-441
[9]   Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care - A randomized trial [J].
Kroenke, K ;
West, SL ;
Swindle, R ;
Gilsenan, A ;
Eckert, GJ ;
Dolor, R ;
Stang, P ;
Zhou, XH ;
Hays, R ;
Weinberger, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (23) :2947-2955
[10]   Combining antidepressants for treatment-resistant depression: A review [J].
Lam, RW ;
Wan, DDC ;
Cohen, NL ;
Kennedy, SH .
JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (08) :685-693